# US 2019/0375798 A1 · Epitope focusing by variable effective antigen surface concentration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375798 A1
- Document ID: US20190375798A1
- Status: Published application
- Kind: A1
- Application number: 16/231,294
- Filed: 2018-12-21
- Published: 2019-12-12
- Earliest claimed: 2012-05-21
- Assignees: Distributed Bio, Inc.
- Applicants: Distributed Bio, Inc.
- Inventors: Jacob E. GLANVILLE
- Web page: https://patentgrep.com/patent/US20190375798A1

## CPC

- C07K 14/005: from viruses
- A61K 38/46: Hydrolases (3)
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G16B 20/30: Detection of binding sites or motifs
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 30/10: Sequence alignment; Homology search
- G16B 35/00: ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16B 35/10: Design of libraries
- G16C 20/60: In silico combinatorial chemistry
- A61K 39/0011: {Cancer antigens}
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 2039/515: {Animal cells}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16071: Demonstrated in vivo effect
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12Y 306/05002: Small monomeric GTPase (3.6.5.2)
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- C12Y: ENZYMES

## Abstract

The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

## Claims

### Claim 1

(canceled)

### Claim 2

A computing device comprising a processor; and data storage, storing instructions that, upon execution by the processor, cause the computing device to perform functions comprising:
a. obtaining a target antigen protein sequence and one or more antigen homolog sequences;
b. obtaining structural models of the target antigen protein sequence and the one or more antigen homolog sequences and identifying a plurality of surface-exposed amino acid residues;
c. generating, in silico, a library of a plurality of antigen variants using the structural models, wherein such generation comprises:
i. diversifying non-target epitope surface exposed amino acid residues for each antigen variant based on the structural models;
ii. performing comparisons between each of a plurality of non-target epitope surface exposed regions comprising a commonly defined area between antigen variants of the library,
wherein antigen variants of the library share at least 30% sequence identity in non surface exposed amino acid residues, and wherein antigen variants of the library share at most 90% sequence identity in non target epitope surface exposed amino acid residues; and
d. selecting six or more antigen variants generated in (c).

### Claim 3 (depends on 1)

The device of claim 1, wherein the functions further comprise, following step (b), aligning the structural models of the target antigen and the one or more antigen homolog sequences to create an alignment.

### Claim 4 (depends on 2)

The device of claim 2, following the step of claim 2, wherein the functions further comprise extracting a weighted score for each amino acid residue frequency of the target antigen protein sequences using the alignment.

### Claim 5 (depends on 3)

The device of claim 3, wherein the weighted score is a positional weight matrix.

### Claim 6 (depends on 4)

The device of claim 4, wherein the positional weight matrix comprises an identity and a frequency of each amino acid permitted at each structurally conserved position in all known variants of the antigen.

### Claim 7 (depends on 3)

The device of claim 3, wherein the functions further comprise, following the step of claim 3, identifying surface exposed amino acid residues using the weighted score.

### Claim 8 (depends on 5)

The device of claim 5, wherein the functions further comprise, following the step of claim 5, identifying amino acid residues of one or more target epitopes using the weighted score.

### Claim 9 (depends on 5)

The device of claim 5, wherein the functions further comprise, following the step of claim 5, identifying one or more target epitopes using the weighted score.

### Claim 10 (depends on 7)

The device of claim 7, wherein the functions further comprise, following the step of claim 7, identifying one or more target epitopes using the weighted score.

### Claim 11 (depends on 1)

The device of claim 1, wherein the target antigen protein sequence comprises the sequence of a: pneumococcal antigen, tuberculosis antigen, anthrax antigen, HIV antigen, seasonal or epidemic flu antigen, Meningococcal antigen, Haemophilus antigen, or a HPV antigen.

### Claim 12 (depends on 1)

The device of claim 1, wherein the library of a plurality of antigen variants comprises at least 1×105 antigen variants.

### Claim 13 (depends on 1)

The device of claim 1, wherein the library of a plurality of antigen variants comprises at least 1×106 antigen variants.

### Claim 14 (depends on 1)

The device of claim 1, wherein the library of a plurality of antigen variants comprises at least 1×107 antigen variants.

### Claim 15 (depends on 1)

The device of claim 1, wherein the data storage is further configured to store at least some of the sequences of the antigens.

### Claim 16 (depends on 1)

The device of claim 1, wherein one or more peripheral devices are in communication with the processor.

### Claim 17 (depends on 1)

The device of claim 1, wherein the device is operatively coupled to a network.

### Claim 18 (depends on 16)

The device of claim 16, wherein the network is an internet, an intranet, an extranet, a telecommunication network, or a data network.
